Trial Profile
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolic acid
- Indications Gastrointestinal disorders; Renal transplant rejection
- Focus Therapeutic Use
- 30 Dec 2019 Status changed from recruiting to discontinued.
- 15 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 15 Jul 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.